Early detection matters! 💗 I'm sharing my personal breast cancer story and how a routine screening mammogram led to an early diagnosis that made all the difference. Watch my story and learn why early detection is so important. Get screened—it could save your life! 🎀 Breast cancer doctor faces her own diagnosis goodmorningamerica.com/video… via @GMA

Over a year ago we lost Felix, a giant in Cancer research to ….Cancer. Let us support @ASCO with a CDA in the honor of Dr Feng. support.conquer.org/p2p/site… #ASCO26 @OncoAlert @ConquerCancerFd

Eric Small’s @ASCOPres Address. Cancer is personal. It affects our families, friends, and neighbors. Translating science to clinics everywhere. #science @ucsfcc

LBA1/Plenary #ASCO26: PROTEUS trial Perioperative apalutamide + ADT vs. placebo + ADT with radical prostatectomy in HR localized or locally advanced PC Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is a key multimodal treatment question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage ! @DanaFarber @DanaFarber_GU @ASCO @OncoAlert

Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304) euoncology.europeanurology.c… In ENZAMET, a post hoc multistate analysis of 1125 men with metastatic hormone-sensitive prostate cancer, discordant radiographic progression without PSA rise occurred in 10% of patients and accounted for 30% of progression events. Discordant progression was associated with worse overall survival. Enzalutamide significantly delayed and reduced risks of discordant and other progression, supporting routine imaging beyond PSA-based monitoring to better detect early radiographic disease progression in clinical practice settings worldwide. #ProstateCancer Andrisha-Jade Inderjeetha Andrew Martin @scserendipity1 @mfrydenberg Lisa G. Horvath @COBLH @GavinMarx1 @crashimminent @MargaretMcJann1 @SandhuShahneen @fverabadillo @MartinStockler @ChrisSweens1 @Prof_IanD @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Sharing insights and learning from the one and only @DrRanaMcKay! This is an uncommon and challenging disease subtype that requires multi-modal care. @PCFnews

Exciting 23 year update from the ERSPC #prostatecancer screening trial from @MoniqueRoobol and team, and a great editorial @VickersBiostats. NND is down to 12 and still falling! And the benefit:harm ratio would be even better w/ modern screening/dx/tx pathways.

When dad (@DrChoueiri) is injured, #ZeinaChoueiri picks it up with her @thayeracademy awesome friends and does the @TheJimmyFund walk to honor @DanaFarber patients and raise money for #cancer #research ! Go @thayeracademy Tigers🐯!

I have been a very fortunate scientist, clinican and human over the past 8 weeks (supported by a wonderful wife) in the kindness shared by those @bethisraellahey @DanaFarber @theNCI @fredhutch @UMNCancer! Thank you to everyone of you 🥰.

I have multiple patients in a similar situation, doing very well on surveillance without the toxicities of hormone therapy.

From @theNCI #PSMA files 73 yo male PSA=17 PSADT=11.6mos PSMA=5+ nodes in pelvis RP & torso (All~5mm). Neg CT and bone scan No🚫Treatment 1 yr later PSA=40 PSADT=13.1 mos PSMA stable across 2 scans over 12 mos #PSMA+ #BCR #ProstateCancer is an indolent process-OK to monitor

Thank you Boston. You have been amazing 🥰

Hi friends, it's #ProstateCancer Friday. Here are Top Posts of the Week! 🧵 1/ Our friend @DrChoueiri on a Sweeney Seminar by @JoshLangMD on CTC:

Reduced Screening May Have Led to Rise in Advanced Prostate Cancer Diagnoses nytimes.com/2025/09/02/scien… via @NYTimes

There are a few truly special places for transformative prostate cancer research. @DanaFarber is one of them. Truly honored to be invited @DrChoueiri @mishabeltran!

Welcoming @JoshLangMD to @DanaFarber Grand Rounds/Seminars in Oncology next week ! cc: @DanaFarber_GU @DanaFarberNews @mishabeltran @ChrisSweens1 @UWCarbone

Excited to share our new study in 𝘾𝙖𝙣𝙘𝙚𝙧 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝! We focus on PROX1 as a key driver of neuroendocrine #ProstateCancer and highlight its potential as a therapeutic target. Huge thanks to @mishabeltran for her mentorship! bit.ly/3HRIvAU @PCF_Science @CDMRP

Advanced Prostate Cancer Alert: Comprehensive large study linking Tanscriptomics and outcomes —Herculean effort from @AttardLab et al in @CellCellPress! sciencedirect.com/science/ar…

A few thoughts on the BARCODE study with Martin Eklund and Ian Thompson: nejm.org/doi/pdf/10.1056/NEJ… Polygenic risk score is a promising adjunct but #prostatecancer screening is still #PSA first!

IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last natera.com/company/news/imvi…